文献速递其他结缔组织病

利妥昔单抗在系统性硬化症中的留存率:一项长期真实世界多中心研究

Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究纳入152例接受利妥昔单抗治疗并随访至少36个月的系统性硬化症患者,中位随访3.3年,5年药物留存率为59.9%(44.6-64.7%)。临床应答是停药首要原因,不良事件影响有限;较短病程、抗拓扑异构酶I阴性、既往无关节炎史与临床应答停药相关,抗着丝点抗体阳性与治疗失败停药相关。

要点

  • 5年利妥昔单抗留存率为59.9%(95%CI 44.6-64.7%),中位随访3.3年。
  • 临床应答为停药最常见原因,发生率为5.7/100患者年(95%CI 3.7-8.4)。
  • 不良事件停药率3.1/100患者年(95%CI 1.7-5.2),对治疗持续性影响有限。

核心结论

  • 利妥昔单抗在系统性硬化症中是安全有效的治疗,临床应答是停药的主要原因,不良事件对治疗持续性的影响有限。
  • 识别与利妥昔单抗应答相关的特定疾病特征将有助于系统性硬化症患者的管理。

研究设计与样本

  • 多中心国家队列真实世界研究,纳入接受利妥昔单抗治疗并随访至少36个月的系统性硬化症患者,进行临床特征描述和纵向监测。
  • 采用竞争风险分析,以亚风险比(sHR)定义探索与利妥昔单抗特定停药原因相关的临床变量。

主要发现

  • 共纳入152例系统性硬化症患者,平均年龄47.3(12.3)岁,女性79.6%,弥漫性疾病77.6%,抗拓扑异构酶I阳性63.2%,中位随访3.3(1.7-5.0)年。
  • 利妥昔单抗主要适应证为间质性肺病(38.8%)、皮肤纤维化加重(36.8%)和关节炎(13.8%),138例(90.8%)接受超过1个疗程。
  • 5年利妥昔单抗留存率为59.9%(44.6-64.7%)。
  • 临床应答是停药最常见原因,发生率为5.7/100患者年(95%CI 3.7-8.4),与较短病程(sHR 0.8;95%CI 0.7-0.9)、抗拓扑异构酶I阴性(sHR 0.4;95%CI 0.2-0.9)、既往指端溃疡(sHR 2.6;95%CI 1.1-6.2)和无关节炎病史(sHR 0.3;95%CI 0.1-0.8)相关。
  • 治疗失败是停药第二大原因,发生率为3.7/100患者年(95%CI 2.2-6.0),与抗着丝点抗体阳性(sHR 2.8;95%CI 1.1-7.4)和抗拓扑异构酶I阴性(sHR 0.2;95%CI 0.1-0.6)相关。

关键数值与推荐

  • 5年利妥昔单抗留存率为59.9%(44.6-64.7%)。
  • 临床应答停药发生率5.7/100患者年(95%CI 3.7-8.4),与较短病程sHR 0.8(95%CI 0.7-0.9)、抗拓扑异构酶I阴性sHR 0.4(95%CI 0.2-0.9)、既往指端溃疡sHR 2.6(95%CI 1.1-6.2)、无关节炎病史sHR 0.3(95%CI 0.1-0.8)相关。
  • 治疗失败停药发生率3.7/100患者年(95%CI 2.2-6.0),与抗着丝点抗体阳性sHR 2.8(95%CI 1.1-7.4)、抗拓扑异构酶I阴性sHR 0.2(95%CI 0.1-0.6)相关。
  • 不良事件停药发生率3.1/100患者年(95%CI 1.7-5.2),与局限皮肤型亚型sHR 3.4(95%CI 1.2-9.7)、既往霉酚酸酯治疗sHR 4.5(95%CI 1.2-16.3)相关。

临床怎么用

  • 作者认为利妥昔单抗在系统性硬化症中是安全有效的治疗,不良事件对治疗持续性的影响有限。
  • 作者认为识别与利妥昔单抗应答相关的特定疾病特征将有助于系统性硬化症患者的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report real-life data on rituximab retention rate as an indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients. METHODS: SSc patients treated with rituximab and followed for at least 36 months were included, clinically characterized and longitudinally monitored. A competing risk analysis with sub-hazard ratio (sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation. RESULTS: One-hundred and fifty-two SSc-patients [mean age 47.3 (12.3) years; females 79.6%; diffuse disease 77.6%; anti-topoisomerase-I positivity 63.2%] were evaluated over a median (interquartile range) time of 3.3 (1.7-5.0) years. The primary indications for rituximab were interstitial lung disease (38.8%), worsening skin fibrosis (36.8%) and arthritis (13.8%); 138 patients (90.8%) received more than one rituximab course. The 5-year rituximab retention rate was 59.9% (44.6-64.7%). Clinical response was the most common reason for rituximab discontinuation [5.7; 95% CI: (3.7-8.4) per 100 patient-years] and was associated with a shorter disease duration (sHR 0.8; 95% CI: 0.7, 0.9), anti-topoisomerase-I negativity (sHR 0.4; 95% CI: 0.2, 0.9), previous digital ulcers (sHR 2.6; 95% CI: 1.1, 6.2) and no history of arthritis (sHR 0.3; 95% CI: 0.1, 0.8). Treatment failure was the second cause of rituximab discontinuation [3.7 (95% CI: 2.2, 6.0) per 100 patient-years] and was associated with anti-centromere antibody positivity (sHR 2.8; 95% CI: 1.1, 7.4) and anti-topoisomerase-I negativity (sHR 0.2; 95% CI: 0.1, 0.6). Adverse events (AEs) were the less common cause of discontinuation [3.1 (95% CI: 1.7, 5.2) per 100 patient-years], associated with limited cutaneous subset (sHR 3.4; 95% CI: 1.2, 9.7) and previous mycophenolate mofetil treatment (sHR 4.5; 95% CI: 1.2, 16.3). CONCLUSION: Rituximab is a safe and effective treatment in SSc: clinical response emerged as the primary reason for rituximab discontinuation, and AEs had a limited impact on treatment persistence. The identification of specific disease features associated with a response to rituximab will be useful in the management of SSc-patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. De Luca G, De Lorenzis E, Campochiaro C, et al. Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study. Rheumatology (Oxford). 2025. PMID: 38745439. doi:10.1093/rheumatology/keae280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。